Evidence map›Paper›PMID 40789776›Full record

ArticleSurgical endoscopy2025

Long-term outcomes in deceased versus living donor liver transplantation for hepatocellular carcinoma: a bi-institutional study of 486 cases.

Fabrizio Di Benedetto, Cristiano Guidetti, Dimitri Aristotle Raptis, Gian Piero Guerrini, Paolo Magistri, Massimo Malagò, Stefano Di Sandro, Dieter Clemens Broering

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fabrizio Di BenedettoHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy. fabrizio.dibenedetto@unimore.it.
Cristiano GuidettiHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy.
Dimitri Aristotle RaptisDepartment of Liver Transplantation and Hepatobiliary Surgery, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Gian Piero GuerriniHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy.
Paolo MagistriHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy.
Massimo MalagòDepartment of Liver Transplantation and Hepatobiliary Surgery, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Stefano Di SandroHepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy.
Dieter Clemens BroeringDepartment of Liver Transplantation and Hepatobiliary Surgery, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC), but access is often limited by organ shortage and prolonged waiting times. Living donor liver transplantation (LDLT) offers timely transplantation and may improve oncologic outcomes compared to deceased donor liver transplantation (DDLT).

methodsThis retrospective cohort study included 486 patients with HCC who underwent LT at two high-volume centers between 2010 and 2020. Outcomes were compared between LDLT and DDLT recipients. Survival analyses were performed using Kaplan-Meier estimates and Cox regression models.

resultsA total of 182 patients received LDLT and 304 received DDLT. Baseline tumor burden and liver function were comparable. LDLT was associated with shorter time to transplant (186 vs. 410 days, p < 0.001), fewer downstaging procedures, and improved survival. Five-year overall survival was 82% for LDLT versus 73% for DDLT (p = 0.010); disease-free survival was 93% versus 83% (p = 0.003). On multivariable analysis, DDLT (HR 3.03, p = 0.017) and BCLC B/C stage (HR 1.98, p = 0.017) were independent predictors of recurrence.

conclusionLDLT is associated with superior long-term outcomes in patients with HCC, independent of tumor stage and timing. These findings support the broader use of LDLT as an effective oncologic strategy.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationLiving DonorsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeHepatocellular carcinomaLiver transplantationLiving donationLiving donor liver transplantOncological outcomes

Identifiers

PMID40789776
PMCPMC12500795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.